John E. Taylor

发表

Erratum: Does gut hormone PVY3-36 decrease food intake in rodents? (Nature (2004) 430 (165) DOI:10.1038/nature03019)

D. Allison, R. Seeley, M. Tschöp, 2004 .

No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure.

S. Anker, M. Culler, R. Datta, 2009, International journal of cardiology.

Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists.

D. Coy, R. Datta, John E. Taylor, 2002, European journal of pharmacology.

Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand.

S. Melmed, M. Culler, S. Ren, 2003, The Journal of clinical endocrinology and metabolism.

Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile.

W. Mitch, D. Marks, Zhaoyong Hu, 2008, Endocrinology.

Somatostatin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

D. Hoyer, S. Schulz, S. Melmed, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.

S. Melmed, M. Culler, K. Wawrowsky, 2007, Molecular endocrinology.

There Are Three Distinct Forms of Bombesin

B. Gibson, A. Falick, E. Spindel, 1996, The Journal of Biological Chemistry.

Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion.

S. Melmed, M. Culler, S. Ren, 2003, The Journal of clinical endocrinology and metabolism.

Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.

D. Hoyer, S. Lamberts, M. Culler, 2005, American journal of physiology. Endocrinology and metabolism.

Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency.

M. Culler, M. Cawthorne, John E. Taylor, 2010, Endocrinology.

Novel analogs of ghrelin: physiological and clinical implications.

T. Horvath, M. Culler, S. Diano, 2004, European journal of endocrinology.

New Tryptophan Derived CCK Antagonists

R. Jensen, John E. Taylor, J. Moreau, 1992 .

Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.

M. Culler, G. Stalla, M. Theodoropoulou, 2008, Endocrine-related cancer.

Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas.

I. Shimon, H. Rubinfeld, M. Culler, 2006, The Journal of clinical endocrinology and metabolism.

Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia.

D. Marks, A. Inui, M. Culler, 2007, Endocrinology.

Chemical synthesis and receptor binding of catfish somatostatin: a disulfide‐bridged β‐d‐Galp‐(1→3)‐α‐d‐GalpNAc O‐glycopeptide*

B. Morgan, John E. Taylor, G. Bárány, 2000 .

The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat

D. Cocchi, V. Locatelli, M. Culler, 2005, Regulatory Peptides.

P. Braquet, John E. Taylor, K. Drieu, 1985 .

A Novel Growth Hormone Secretagogue-1a Receptor Antagonist That Blocks Ghrelin-Induced Growth Hormone Secretion but Induces Increased Body Weight Gain

T. Horvath, M. Culler, S. Diano, 2005, Neuroendocrinology.

Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line.

M. Culler, John E. Taylor, M. Bondanelli, 2002, Biochemical and biophysical research communications.

Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: Evidence for SSTR2 heterogeneity

R. Bashirzadeh, T. Reisine, John E. Taylor, 1994, Peptides.

A GHS-1a Receptor Agonist that is Highly Effective in Stimulating Body Weight Gain

M. Culler, R. Datta, H. Halem, 2006 .

Pharmacology of GRF and Somatostatin: Positive and Negative Control of GH Release

D. Coy, S. Hocart, John E. Taylor, 1994 .

Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells

M. Culler, M. Stridsberg, K. Öberg, 2004, Medical oncology.

Identification and Characterization of Somatostatin (SRIF), Gastrin Releasing Peptide (GRP), and Neuromedin B (NMB) Receptors on Established Tumors and Tumor Cell Lines

John E. Taylor, 1993 .

Kathy, P. Braquet, Étienne, 1985 .

Receptor-selective somatostatin (SRIF) analogs

D. Coy, M. Heiman, John E. Taylor, 1988 .

CHAPTER 18 – NEUROCHEMICAL AND NEUROPHARMACOLOGICAL ASPECTS OF HISTAMINE RECEPTORS

John E. Taylor, 1985 .

Neurochemical and neuropharmacological aspects of histamine receptors

John E. Taylor, 1982, Neurochemistry International.

Interactions of verapamil, D 600, flunarizine and nifedipine with cerebral histamine-receptors

F. V. Defeudis, John E. Taylor, F. Defeudis, 1986, Neurochemistry International.

Real-Time Evaluation of Somatostatin Subtype 2 Receptor Activity Employing the Technique of Cytosensor Microphysiometry

John E. Taylor, C. Woon, R. Nelson, 1996, Peptides.

Exploration of the DTrp-NMeLys motif in the search for potent somatostatin antagonists.

D. Coy, John E. Taylor, W. Murphy, 2002, Bioorganic & medicinal chemistry.

Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro.

A. Bottoni, M. Culler, L. Cavazzini, 2004, The Journal of clinical endocrinology and metabolism.

Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation.

M. Culler, F. Minuto, John E. Taylor, 2005, American journal of physiology. Endocrinology and metabolism.

Interactions of trimebutine with guinea‐pig opioid receptors

J. Junien, John E. Taylor, F. Roman, 1987, The Journal of pharmacy and pharmacology.

Agonist Regulation of Muscarinic Acetylcholine Receptors in Rat Spinal Cord

T. Yaksh, E. Richelson, John E. Taylor, 1982, Journal of neurochemistry.

RECEPTOR-MEDIATED CYCLIC GMP FORMATION BY AN ADRENERGIC CLONE (NIE-115) OF MOUSE NEUROBLASTOMA

E. Richelson, John E. Taylor, 1979 .

Histamine H1 receptors in the brain and spinal cord of the cat

T. Yaksh, E. Richelson, John E. Taylor, 1982, Brain Research.

Somatostatin Receptor Type 5 Modulates Somatostatin Receptor Type 2 Regulation of Adrenocorticotropin Secretion*

Kolja A. Wawrowsky, S. Melmed, M. Culler, 2005, Journal of Biological Chemistry.

Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125

D. Cocchi, M. Culler, R. Datta, 2007, Pituitary.

Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells

M. Cattaneo, J. Taylor, M. Culler, 2000, FEBS letters.

[Psi13,14] Bombesin Analogues Inhibit Growth of Small Cell Lung Cancer in Vitro and in Vivo

T. Moody, J. Staley, J. Mulshine, 1991 .

GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity

R. Jensen, D. Coy, Tetsuhide Ito, 2001, Peptides.

Somatostatin receptors in GtoPdb v.2023.1

D. Hoyer, S. Schulz, S. Melmed, 2023, IUPHAR/BPS Guide to Pharmacology CITE.

Synthesis and binding potencies of cyclohexapeptide somatostatin analogs containing naphthylalanine and arylalkyl peptoid residues

J. Taylor, B. Morgan, John E. Taylor, 1999, Journal of peptide science : an official publication of the European Peptide Society.

First neuromedin B receptor antagonists are based on somatostatin octapeptide analogues

R. Jensen, D. Coy, John E. Taylor, 1994 .

Investigation of the anxiolytic effects of linalool, a lavender extract, in the male Sprague-Dawley rat.

John E. Taylor, T. Ceremuga, S. Bracken, 2008, AANA journal.

A structure-based design approach to the development of novel, reversible AChE inhibitors.

J L Sussman, I Silman, J. Sussman, 2001, Journal of medicinal chemistry.

Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition.

G. Gores, N. LaRusso, D. Nagorney, 1995, Gastroenterology.

Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.

J. Taylor, M. Culler, H. Dufour, 2005, European journal of endocrinology.

Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.

S. Melmed, I. Shimon, J. Taylor, 1997, The Journal of clinical investigation.

Development of feeding and Y-1 NPY receptor antagonists

W. Chance, John E. Taylor, S. Sheriff, 2002 .

Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists

T. Moody, J. Staley, J. Taylor, 1992, Peptides.

Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.

J. Taylor, M. Culler, A. Barlier, 2002, The Journal of clinical endocrinology and metabolism.

Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist.

J. Taylor, D. Coy, S. Hocart, 2001, Journal of medicinal chemistry.

In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue.

A. Bogdén, J. Taylor, D. Coy, 1988, Biochemical and biophysical research communications.

PYY3‐36 as an anti‐obesity drug target

D. Allison, R. Seeley, M. Tschöp, 2005, Obesity reviews : an official journal of the International Association for the Study of Obesity.

Response of human lung tumor xenografts to treatment with a somatostatin analogue (Somatuline).

A. Bogdén, J. Taylor, D. Coy, 1990, Cancer research.

Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.

S. Melmed, Xinmin Yan, I. Shimon, 1997, The Journal of clinical investigation.

There Are Three Distinct Forms of Bombesin IDENTIFICATION OF [Leu 13 ]BOMBESIN, [Phe 13 ]BOMBESIN, AND [Ser 3 ,Arg 10 ,Phe 13 ]BOMBESIN IN THE FROG BOMBINA ORIENTALIS *

B. Gibson, A. Falick, E. Spindel, 1996 .

Novel ghrelin analogs with improved affinity for the GH secretagogue receptor stimulate GH and prolactin release from human pituitary cells.

I. Shimon, H. Rubinfeld, J. Taylor, 2004, European journal of endocrinology.